These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20568071)

  • 1. [Livedo reticularis following subcutaneous injection of interferon beta-1b].
    Rodríguez-Vico JS; Mendoza A; Duarte J
    Rev Neurol; 2010 Jul; 51(1):62. PubMed ID: 20568071
    [No Abstract]   [Full Text] [Related]  

  • 2. Cutaneous reactions following subcutaneous beta-interferon-1b injection.
    Ohata U; Hara H; Yoshitake M; Terui T
    J Dermatol; 2010 Feb; 37(2):179-81. PubMed ID: 20175855
    [No Abstract]   [Full Text] [Related]  

  • 3. Recurrent injection site reactions from interferon beta 1-b.
    Samuel L; Lowenstein EJ
    J Drugs Dermatol; 2006 Apr; 5(4):366-7. PubMed ID: 16673806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
    Baum K; O'Leary C; Coret Ferrer F; Klímová E; Procházková L; Bugge J;
    Mult Scler; 2007 Nov; 13(9):1153-60. PubMed ID: 17967843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Retinopathy secondary to treatment with Interferon beta-1a in a patient with multiple sclerosis].
    Mallada-Frechín J; Abellán-Miralles I; Alfaro-Beltra ML; Medrano V; Muñoz-Gil MB; Fernández-Izquierdo S; Piqueras-Rodríguez L
    Rev Neurol; 2005 Apr 16-30; 40(8):482-4. PubMed ID: 15861330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon beta-1b (Extavia) for multiple sclerosis.
    Med Lett Drugs Ther; 2010 Nov; 52(1350):86-7. PubMed ID: 21045760
    [No Abstract]   [Full Text] [Related]  

  • 7. Interferons beta have vasoconstrictive and procoagulant effects: a woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis.
    Rot U; Ledinek AH
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S79-81. PubMed ID: 24321162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interferons beta in patients with multiple sclerosis].
    Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
    [No Abstract]   [Full Text] [Related]  

  • 9. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
    Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
    Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
    J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
    Nakamura Y; Kawachi Y; Furuta J; Otsuka F
    Eur J Dermatol; 2008; 18(5):579-82. PubMed ID: 18693165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interferon therapy of multiple sclerosis].
    Jensen D
    Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Superiority of interferon beta-1b in comparison with interferon beta-1a in multiple sclerosis. 2 years outcomes reveal that clinical advantages increase over time].
    Krankenpfl J; 2001; 39(10-12):332-4. PubMed ID: 11858146
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a.
    Pohl D; Rostasy K; Gärtner J; Hanefeld F
    Neurology; 2005 Mar; 64(5):888-90. PubMed ID: 15753430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients.
    Kümpfel T; Schwan M; Pollmächer T; Yassouridis A; Uhr M; Trenkwalder C; Weber F
    Mult Scler; 2007 Nov; 13(9):1138-45. PubMed ID: 17967841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin K cream reduces reactions at the injection site in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon beta - VIKING study.
    Lanzillo R; Moccia M; Carotenuto A; Vacchiano V; Satelliti B; Panetta V; Brescia Morra V
    Mult Scler; 2015 Aug; 21(9):1215-6. PubMed ID: 25662354
    [No Abstract]   [Full Text] [Related]  

  • 17. Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases.
    Ball NJ; Cowan BJ; Hashimoto SA
    J Cutan Pathol; 2009 Mar; 36(3):331-7. PubMed ID: 19032383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
    Panitch H; Goodin D; Francis G; Chang P; Coyle P; O'Connor P; Li D; Weinshenker B;
    J Neurol Sci; 2005 Dec; 239(1):67-74. PubMed ID: 16169561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatigue and cognition in patients with relapsing multiple sclerosis treated with interferon β.
    Melanson M; Grossberndt A; Klowak M; Leong C; Frost EE; Prout M; Le Dorze JA; Gramlich C; Doupe M; Wong L; Esfahani F; Gomori A; Namaka M
    Int J Neurosci; 2010 Oct; 120(10):631-40. PubMed ID: 20942577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis.
    Serarslan G; Okuyucu E; Melek I; Hakverdi S; Duman T
    Mult Scler; 2008 Mar; 14(2):259-61. PubMed ID: 18337427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.